Safety considerations with biologics and new inflammatory bowel disease therapies

NSF Queiroz, M Regueiro - Current Opinion in Gastroenterology, 2020 - journals.lww.com
Safety considerations with biologics and new inflammatory bo... : Current Opinion in
Gastroenterology Safety considerations with biologics and new inflammatory bowel disease …
被引用次数：31 相关文章

[引用][C] Safety considerations with biologics and new inflammatory bowel disease therapies

NSF QUEIROZ, M REGUEIRO - Current Opinion in …, 2020 - observatorio.fm.usp.br
Purpose of review The safety profile of therapies is an important issue that should always be
shared with patients when choosing their treatment. The introduction of biologics over the …

Safety considerations with biologics and new inflammatory bowel disease therapies

NSF Queiroz, M Regueiro - Current opinion in …, 2020 - pubmed.ncbi.nlm.nih.gov
Purpose of review The safety profile of therapies is an important issue that should always be
shared with patients when choosing their treatment. The introduction of biologics over the …

Safety considerations with biologics and new inflammatory bowel disease therapies

NSF Queiroz, M Regueiro - Current Opinion in Gastroenterology, 2020 - journals.lww.com
Safety considerations with biologics and new inflammatory bo... : Current Opinion in
Gastroenterology Safety considerations with biologics and new inflammatory bowel disease …

Safety considerations with biologics and new inflammatory bowel disease therapies.

NSF Queiroz, M Regueiro - Current Opinion in Gastroenterology, 2020 - europepmc.org
Safety considerations with biologics and new inflammatory bowel disease therapies. - Abstract
- Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …